A Study of Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Response to Their Current Biologic Agent Regimen

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

252 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-09-30

Study Completion Date

2022-03-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This multicenter, prospective, observational, single-arm, 26-week study will evaluate the effectiveness, safety and tolerability of brodalumab subcutaneous injection in participants with psoriasis with inadequate response to their current biologic agent regimen.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Canadian Real World Evidence Study of Brodalumab in Plaque Psoriasis to Understand the Impact on Quality of Life and Work Productivity

NCT05132231

Psoriasis

ACTIVE_NOT_RECRUITING

LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe Psoriasis

NCT03254667

Psoriasis

ENROLLING_BY_INVITATION

Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed IL-17A Therapies

NCT03403036

Psoriasis

COMPLETED PHASE4

Treatment of Moderate Hidradenitis Suppurativa

NCT03910803

Hidradenitis Suppurativa

UNKNOWN PHASE2

Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis

NCT03897075

Chronic Plaque Psoriasis Moderate to Severe Nail Psoriasis

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Psoriasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Brodalumab 210 mg Q2W

Participants will receive brodalumab 210 milligrams (mg) administered as 1 subcutaneous injection at Day 1 and at Weeks 1 and 2 followed by 210 mg every 2 weeks (Q2W) thereafter until Week 26.

Brodalumab

Intervention Type DRUG

Brodalumab will be administered per dose and schedule specified in the arm.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Brodalumab

Brodalumab will be administered per dose and schedule specified in the arm.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

SILIQ®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participant has enrolled in the brodalumab patient support program (PSP).
* Participant has provided informed consent, using an Independent Ethics Committee (IEC) or Institutional Review Board (IRB) approved Informed Consent Form (ICF).
* Confirmed diagnosis with moderate to severe plaque psoriasis.
* On stable treatment with a biologic for a minimum of 12 weeks, and not having achieved adequate therapeutic response, as per the investigator's judgment, for example BSA of greater than or equal to (≥) 1% and physicians global assessment (PGA) of ≥3.
* Participant must be able to understand and communicate with the investigator, as well as complete the study questionnaires, in one of the available and validated languages.
* Participants participating in other observational studies or registries are permitted to enroll in this study at the same time.

Exclusion Criteria

* Receiving or has received any investigational drug (or is currently using an investigational device) within 30 days or 5 drug half-lives (whichever is longer) prior to receiving the first dose of brodalumab (Day 1).
* Participant has a history of any psychiatric disorder or substance abuse that, in the opinion of the investigator, would pose a risk to participant safety or interfere with the study evaluation, procedures, or completion.
* Participant has previous history of suicidal ideation and/or behavior or report suicidal ideation and/or behavior during the study.
* Presence of any other serious and/or uncontrolled medical condition that, in the opinion of the investigator, prohibits the participant from participating in the study.
* Participant has a body mass index (BMI) greater than (\>) 40 kilograms/square meter (kg/m\^2) during the screening phase or during the study.
* Any contraindication as per the product monograph: Brodalumab injection is contraindicated in participants with clinically significant hypersensitivity to brodalumab or to any of the excipients or component of the container. Brodalumab is contraindicated in participants with Crohn's disease.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No